{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:43:51Z","timestamp":1784735031633,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":282,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["202103021224001"],"award-info":[{"award-number":["202103021224001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Shanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["202103021224001"],"award-info":[{"award-number":["202103021224001"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100550","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:57:19Z","timestamp":1760223439000},"page":"100550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification"],"prefix":"10.1016","volume":"24","author":[{"given":"Jiajia","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lrr.2025.100550_bib0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2025.100550_bib0002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Na?ve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine","volume":"140","author":"Hartmut","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.lrr.2025.100550_bib0003","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2025.100550_bib0005","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na\u00efve Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.lrr.2025.100550_bib0006","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.lrr.2025.100550_bib0008","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.lrr.2025.100550_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0010","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.lrr.2025.100550_bib0011","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2024","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.lrr.2025.100550_bib0012","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2025.100550_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lrr.2025.100550_bib0014","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"D\u00f6hner","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0015","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0017","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.lrr.2025.100550_bib0018","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.lrr.2025.100550_bib0019","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.lrr.2025.100550_bib0020","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lrr.2025.100550_bib0021","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax\u2009+\u2009Hypomethylating Agent","volume":"100","author":"Gangat","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0022","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/bjh.19292","article-title":"Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study","volume":"204","author":"Miyashita","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.lrr.2025.100550_bib0023","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lrr.2025.100550_bib0024","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.lrr.2025.100550_bib0025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"S\u00e9bert","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2025.100550_bib0026","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0027","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-023-00818-6","article-title":"Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Al-Kali","year":"2023","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0028","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.lrr.2025.100550_bib0029","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1002\/ajh.26730","article-title":"Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1","volume":"97","author":"Wright","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/ejh.13979","article-title":"Impact of secondary-type mutations in NPM1 mutated AML","volume":"111","author":"Zhou","year":"2023","journal-title":"Eur J Haematol"},{"issue":"15","key":"10.1016\/j.lrr.2025.100550_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70102","article-title":"Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients","volume":"13","author":"Wu","year":"2024","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0032","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010198","article-title":"The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation","volume":"15","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0034","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2025.100550_bib0035","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0036","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.5001\/omj.2023.126","article-title":"IDH1 and IDH2 Gene Mutations in Omani Patients with Acute Myeloid Leukemia: Prognostic Significance and Clinic-pathologic Features","volume":"39","author":"Al Abri","year":"2024","journal-title":"Oman Med J"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0037","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.lrr.2025.100550_bib0038","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.lrr.2025.100550_bib0039","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.lrr.2025.100550_bib0040","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.lrr.2025.100550_bib0041","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2025.100550_bib0042","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lrr.2025.100550_bib0043","first-page":"202","article-title":"Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis","volume":"15","author":"Sheikhi","year":"2024","journal-title":"Caspian J Intern Med"},{"issue":"9","key":"10.1016\/j.lrr.2025.100550_bib0044","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1016\/j.sjbs.2021.07.012","article-title":"RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients","volume":"28","author":"Rehman","year":"2021","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.lrr.2025.100550_bib0046","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0047","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/hematology.2022000354","article-title":"Transplant for TP53-mutated MDS and AML: because we can or because we should?","volume":"2022","author":"Versluis","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"10.1016\/j.lrr.2025.100550_bib0048","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2025.100550_bib0049","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s44313-025-00054-w","article-title":"Correction: Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia\u2011related genes mutations and TP53 aberrations","volume":"60","author":"Kim","year":"2025","journal-title":"Blood Res"},{"issue":"8","key":"10.1016\/j.lrr.2025.100550_bib0050","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia With Venetoclax and Azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lrr.2025.100550_bib0051","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.lrr.2025.100550_bib0052","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","article-title":"Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation","volume":"7","author":"Short","year":"2023","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.1016\/j.lrr.2025.100551","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000}},{"DOI":"10.1016\/j.lrr.2025.100551","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:46:30Z","timestamp":1764852390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":52,"alternative-id":["S2213048925000524"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100550","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100550"}}